Also see: Citi, Peabody: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES

Arch Capital ( ACGL) estimates were cut through 2011 at UBS. Reflects an increase of the second-quarter 2011 catastrophe loss estimate, UBS said. Maintain Neutral rating and $34 price target.

Cliffs Natural Resources ( CLF) estimates were increased through 2013 at UBS. Company announces phase III development of Bloom Lake, UBS said. Maintain Neutral rating and $34 price dtarget.

Campbell Soup ( CPB) estimates, target were raised at Goldman Sachs. Shares now seen reaching $34, and estimates were also increased, as a restructuring program was announced, Goldman said. Neutral rating.

Goldman Sachs ( GS) numbers were lowered through 2013 at Credit Suisse. Company is facing difficult market conditions, Credit Suisse said. Outperform rating and new $170 price target.

Harsco ( HSC) price target was cut at Jefferies to $38. Infrastructure business is still a work in progress, Jefferies said. Buy rating.

Maidenform ( MFB) estimates, target were lowered at Citigroup. Shares now seen reaching $38. Estimates were also lowered, as sales have not been as robust as expected, Citigroup said. Buy rating.

Morgan Stanley ( MS) numbers were reduced at Credit Suisse. Shares now seen reaching $33. Estimates also cut, given tougher market conditions, Credit Suisse said. Outperform rating.

Nike ( NKE) estimates, target raised at Citigroup. Shares now seen reaching $98, according to Citigroup. Estimates also increased on renewed apparel growth and innovation in footwear. Buy rating.

Progress Energy ( PGN) target cut at Jefferies. Shares of PGN now seen reaching $48.50, according to Jefferies. Company could face delays at Crystal River, Jefferies said. Hold rating.

Rowan ( RDC) estimates were cut through 2012 at UBS. Reflects closing of LTI sale and fleet status update. Maintain Buy rating and $50 price target.

Sigma Designs ( SIGM) estimates, target were reduced at UBS. Shares now seen reaching $8.50. Estimates also lowered on IPTV segment recovery and sales mix uncertainties, UBS said. Maintain Neutral rating.

SYNNEX ( SNX) estimates, target cut at Goldman Sachs. Shares now seen reaching $33. Estimates also lowered citing Japan weakness, Goldman said. Neutral rating.

Watson Pharmaceuticals ( WPI) estimates, target raised at Morgan Stanley. Shares now seen reaching $78, according to Morgan Stanley. Estimates also increased on lower-than-expected royalties on Concerta and Specifar accretion, Morgan Stanley added. Overweight rating.

End of report.
This article was written by a staff member of TheStreet.

If you liked this article you might like

Market Recon: The Foundation Is Laid to Support This Rally

Turn to Insurers for Some Portfolio Insurance

AIG's Sale of United Guaranty Better-than-Expected, Executes Streamlining Plan

AIG's $3.4B United Guaranty Sale to Drive Buyback Hike

ACGL, BAP And TRV, 3 Financial Stocks Pushing The Sector Lower